消息面上，7月31日，央视新闻在其发布的"国家医保局支持脑机接口等新技术进入临床并收费"报道中 提到，为鼓励药品研发创新，国家医保局制定了"新上市药品首发价格机制"。这是自去年新上市化学药 品首发价格机制征求意见之后，国家医保局首次公开"新上市药品首发价格机制"已在政策层面建立。 展望后市，多家机构对创新药行情仍普遍持相对乐观态度。中信证券认为，我国创新药发展已经取得阶 段性成效，《支持创新药高质量发展的若干措施》有利于进一步完善支持创新药高质量发展。兴业证券 表示，创新药板块景气度可持续，"创新+国际化"创新药产业趋势不变，始终是医药板块的核心方向， 政策支持+全球竞争力持续加强+商业化盈利兑现。(魏昭宇) 中证网讯8月首个交易日，市场早盘冲高回落，主要指数小幅下跌。上证指数午盘跌0.19%。而受医保 局首次确认"新上市药品首发价格机制"政策利好影响，创新药概念持续走强，多股创出历史新高。截至 午间收盘，嘉实"超级ETF"货架上的"医药三剑客"：生物疫苗ETF(562860)、科创医药ETF嘉实(588700) 和恒生医疗ETF嘉实(159557)涨幅均超0.5%，分别达0.80%、0.68%、0.58%。 ...

1日早盘，沪指盘中窄幅震荡，深证成指、创业板指回落翻绿，场内近3000股飘红。 （文章来源：证券时报网） 盘面上看，旅游、石油、半导体等板块走低，物流板块拉升，医药、环保、农业等板块上扬，辅助生 殖、创新药、光伏产业链股活跃。 东莞证券表示，连续反弹后，沪指近期在3600点上方遇阻，短线存在一定的抛压释放，特别是创业板指 收出两连阴，显示短期休整压力加大，而从统计局最新公布的PMI数据来看，7月份经济数据或有所走 弱，也对基本面带来一定压制，短线需要注意市场的震荡反复。展望中期，7月底政治局会议定调偏积 极，在外部经贸摩擦缓和预期、国内稳增长政策持续发力以及流动性环境维持合理充裕的多重因素驱动 下，中期市场仍将保持稳定。 截至午间收盘，沪指跌0.19%报3566.55点，深证成指跌0.15%，创业板指跌0.16%，科创50指数跌 0.84%，沪深北三市合计成交10082亿元。 ...

Focus Events - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has become the first company to have its IPO application accepted under the reactivated fifth listing standard of the Sci-Tech Innovation Board, focusing on innovative biopharmaceuticals for blood product alternatives [1] - Joy City Property plans to repurchase shares at HKD 0.62 per share, with a total amount of approximately HKD 29.32 billion, and will apply for the cancellation of its listing status on the Hong Kong Stock Exchange [3] - Microsoft has surpassed a market capitalization of USD 4 trillion, becoming the second company globally to achieve this milestone [3] Macro News - The National Development and Reform Commission emphasizes the need to deepen the construction of a unified national market and eliminate "involution" competition [8] - The Ministry of Commerce states that China and the U.S. will continue to promote the extension of previously suspended tariffs and countermeasures for 90 days, aiming to stabilize economic relations [10] Industry Dynamics - The domestic gaming market in China achieved a sales revenue of RMB 168 billion in the first half of 2025, marking a year-on-year growth of 14.08% and setting a historical record [10] - The National Medical Insurance Administration supports high-level innovative drugs by establishing a price stability period to ensure reasonable returns during the initial market phase [10] Company Focus - Sanhui Electric has signed a framework sales contract for robot products with Zibo Blue Ribbon Health Management Co., Ltd., with a commitment to sell at least 50 units in 2025 and 450 units by 2027 [12] - Henan Shuanghui Investment Development Co., Ltd. has signed a cooperation agreement with Henan Huirun Food Co., Ltd., expecting an annual output value of RMB 1.7 billion from the project [12] - Wukuang Securities has appointed Zheng Yu as the new chairman, who will also serve as the general manager, consolidating leadership roles [13] - Sinopec expects a net profit of RMB 20.1 billion to RMB 21.6 billion for the first half of 2025, impacted by falling international oil prices and competitive market conditions [14] - Shanying International plans to establish a partnership enterprise with a capital contribution of RMB 2.977 billion, aiming to attract long-term investors [15] - Shima Holdings intends to acquire a 10.27% stake in Nylon Chemical for RMB 952 million, increasing its ownership from 61.79% to 72.06% [18] - Ju Yi Technology has successfully won a bid for the Xiaopeng Huitian flying car factory project, applying innovative technologies for production [20]

Core Viewpoint - The innovative drug sector is experiencing a rebound after a period of adjustment, with significant gains in the Hang Seng Hong Kong Stock Connect Innovative Drug Index and notable performances from various companies [1] Group 1: Market Performance - As of 10:13, the Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 0.6% [1] - Notable stock performances include Lepu Biopharma-B up 4.5%, Ascentage Pharma-B up 4.0%, CSPC Pharmaceutical Group up 3.4%, Livzon Pharmaceutical Group up 3.1%, and CanSino Biologics up 2.7% [1] - The Hang Seng Innovative Drug ETF (159316) has seen net inflows for 13 consecutive trading days, reaching a record size of nearly 1 billion yuan [1] Group 2: Company Announcements - Haikang Pharmaceutical announced that its innovative drug HSK3486 (环泊酚注射液) has received FDA acceptance for its marketing application [1] - Huahai Pharmaceutical reported that its subsidiaries Huyao Tai and Huabo Biotech have received clinical trial approval from the National Medical Products Administration for the world's first dual-target antibody drug HB0043 targeting IL-17A and IL-36R [1] Group 3: Investment Opportunities - The achievements of innovative drug companies in China are noteworthy, indicating potential investment opportunities in the sector [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index reflects the performance of stocks related to innovative drug research, development, and production, focusing on leading companies in the Hong Kong innovative drug market [1] - The Hang Seng Innovative Drug ETF (159316) is the first ETF tracking this index, offering high elasticity and scarcity, allowing investors to benefit from the growth of the innovative drug industry [1]

Group 1: Market Overview - The U.S. stock market indices closed lower, while the China concept index rose by 0.66%. Hong Kong's three major indices opened slightly lower, with the Hang Seng Index down 0.12% and the Hang Seng Tech Index down 0.09% [1] - Some innovative drug concept stocks experienced declines, including BeiGene, Innovent Biologics, and WuXi AppTec, while the Hong Kong Innovative Drug Selected ETF showed active trading with a nearly 1.5% increase [1] Group 2: Industry Opportunities - The Chinese innovative drug industry is undergoing a strategic transition driven by demographic changes, policy incentives, and technological breakthroughs, entering a golden period of rapid development. By 2024, the population aged 65 and above in China is expected to exceed 220 million, accounting for 15.6% of the total population, leading to a significant increase in clinical demand for unmet medical needs [1][2] - The policy framework has been strengthened, with the government report including the "formulation of an innovative drug catalog" as a national strategy, and the National Medical Insurance Administration achieving a 90% success rate in innovative drug negotiations [2] Group 3: Industry Milestones - Chinese innovative drug companies have transformed from technology followers to global innovators, with overseas licensing transaction upfront payments reaching $5.7 billion in 2024, accounting for 20% of the global biopharmaceutical licensing upfront payments [4] - Notable transactions include 3SBio's licensing of a PD-1/VEGF dual antibody to Pfizer for $1.25 billion, marking a record for Chinese dual antibody drugs [4] Group 4: Index Construction - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index employs a rigorous filtering mechanism to ensure the purity of innovation among its constituents [6][7] - The index uses natural language processing (NLP) to quantify companies' innovation relevance, systematically excluding the bottom 5% of "pseudo-innovative" firms [7] Group 5: Weighting Logic - The index's weighting system reflects a deep understanding of the innovative drug industry's nature, with a cap of 15% on individual stock weight to prevent excessive risk exposure [8] - The top five constituent stocks are limited to a combined weight of no more than 60%, balancing concentration and risk diversification [8] Group 6: Investment Value Validation - In the first half of 2025, the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index achieved a cumulative return of 58.95%, significantly outperforming the Hang Seng Index and the CSI 300 Index [10][11] - The index's price-to-book (PB) ratio was 3.09, showing recovery potential, while the price-to-sales (PS) ratio was 2.88, indicating a valuation discount of over 40% compared to international peers [11] Group 7: Capital Flow Insights - In Q2 2025, southbound funds showed selective inflows into the healthcare sector, with 80% of the top ten net purchases being index constituents [12] - Notable net purchases included $7.8 billion for the leading GLP-1 company and $5.2 billion for the ADC pioneer [12] Group 8: Strategic Allocation - The index's design provides a unique competitive advantage, with strong correlations to R&D intensity and pipeline progress [15] - Different risk-averse investors can adopt varied allocation strategies, such as using the Hong Kong Innovative Drug Selected ETF for long-term positions or focusing on the index's correlation with the NASDAQ Biotechnology Index for trend trading [15]

Market Overview - The A-share market showed mixed results with the Shanghai Composite Index down 0.02% and the Shenzhen Component Index up 0.45% as of the report [3][4] - The innovation drug concept stocks surged, while sectors like aerospace, oil and gas, and stablecoins experienced declines [5][12] Innovation Drug Sector - The innovation drug concept stocks saw significant gains, with companies like Shuyou Shen, Guanhao Biology, and Kexing Pharmaceutical leading the rise [10][11] - The sector's strong performance is attributed to the National Healthcare Security Administration's establishment of a new pricing mechanism for newly listed drugs, encouraging pharmaceutical innovation [14] Silicon Energy Sector - The silicon energy sector experienced a notable rally, with polysilicon futures rising sharply after previously dropping over 4% [16][20] - Companies such as Shuangliang Energy and Aotewei saw their stock prices increase significantly, with Shuangliang Energy hitting the daily limit [18][19] Hong Kong Market - The Hong Kong market showed a slight decline in the Hang Seng Index, although companies like NIO and Baidu saw gains of over 2% [7][8] Key Stock Performances - In the innovation drug sector, notable stock performances included: - Shuyou Shen at 56.30, up 8.29% - Guanhao Biology at 18.69, up 7.41% - Kexing Pharmaceutical at 56.88, up 6.82% [10][11] - In the silicon energy sector, key performers included: - Shuangliang Energy at 6.13, up 10.05% - Aotewei at 36.33, up 10.09% - Daqing Energy at 28.03, up 8.22% [18][19]

央视网消息：8月1日（星期五）上午，国家发展改革委召开国家发展改革委新闻发布会，解读当前经济 形势和经济工作。 国民经济综合司司长周陈介绍，今年以来，在以习近平同志为核心的党中央坚强领导下，我们积极应对 急剧变化的外部环境，打好政策"组合拳"，去年9月26日一揽子增量政策以及今年出台的稳就业稳经济 若干举措接续发力，上半年我国经济在顶住外部压力、消化累积风险的情况下，稳中有进、好于预期， 高质量发展取得新成效，发展的"含金量"不断提高。 关于下一步经济工作，7月30日召开的中央政治局会议已作出全面部署，国家发展改革委将坚决抓好贯 彻落实，努力完成全年经济社会发展预期目标和"十四五"规划各项任务，为"十五五"良好开局打下基 础。 一方面，持续发力、适时加力实施好已部署的各项政策举措，坚定不移实施扩大内需战略，坚定不移推 动高水平科技自立自强，深化改革开放，加力建设全国统一大市场，特别是继续推动稳就业稳经济若干 举措陆续出台实施，保持政策连续性、稳定性，增强灵活性、预见性，将外部压力转化为内生动力，稳 住经济大盘。 另一方面，加强经济监测预测预警，常态化开展政策预研储备，不断完善稳就业扩内需政策工具箱，根 据外部 ...

Group 1 - The Hong Kong stock market has been active since early 2025, even leading global markets at one point, with an average daily trading volume increasing by approximately 80% compared to the same period last year [1] - Despite a weakening overall Chinese economic outlook and ongoing external disturbances, a structural market rally has been observed, with sectors like AI, new consumption, and innovative pharmaceuticals significantly outperforming most broad-based indices in the A-share market [1] - The Hang Seng Technology Index's price-to-earnings ratio (PE TTM) remains at 21 times, indicating a value opportunity, particularly in the e-commerce and local living sectors, which are showing signs of bottoming out [1] Group 2 - The Hong Kong Technology ETF (code: 513020) tracks the Hong Kong Stock Connect Technology Index (code: 931573), which selects up to 50 high-quality companies from the technology sector listed under the Stock Connect program [1] - The index aims to reflect the overall performance of publicly traded companies in the technology sector that can be invested in through the Hong Kong Stock Connect, showcasing significant growth potential and market volatility characteristics [1]

科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创 板创新药指数，以高成长biotech为主，这些企业管线潜力大、研发投入强，指数创新属性突出，有助于 更精准捕捉行业核心成长动能。指数表现弹性较强，产品20%涨跌幅限制使其更贴合板块波动，是成长 型投资者分享创新药红利的便捷选择。 消息面上，为鼓励药品研发创新，国家医保局制定了"新上市药品首发价格机制"。 相关机构表示，我国创新药产业近年来在全球舞台上绽放出蓬勃的发展活力，2025 年更是在多个 维度实现了突破性进展。从出海进程的加速推进，到在 ASCO 大会等国际学术舞台上的亮眼表现，再 到国内政策红利的持续释放，创新药行业正步入黄金发展阶段。当下市场活跃资金对创新药行业的关注 度也日益攀升，为行业的进一步发展注入了强劲动力。 展望后市，创新药行业在出海持续突破、政策红利不断释放以及中国创新药企业研发实力稳步提升 的多重驱动下，正迎来广阔的发展空间，具备较好的投资机会。想要把握创新药行业高成长潜力与国际 化浪潮机遇的小伙伴们，可以关注科创创新药 ETF 国泰（589720）。 注：如提及个股仅供参考，不代表投资建 ...

Group 1 - The core viewpoint of the article highlights the resurgence of the innovative drug sector, with significant stock price increases for companies like Weikang Pharmaceutical and Yuekang Pharmaceutical, indicating a positive market sentiment [1] - The pharmaceutical sector is experiencing a shift in policy attitudes, with optimization of centralized procurement rules, which is expected to benefit the industry [1] - After years of R&D investment, the pharmaceutical pipeline is entering a harvest phase, and there is an accelerating trend of overseas business development (BD) in the industry, showcasing the global competitiveness of China's innovative drugs [1] Group 2 - Zhongyin Securities suggests focusing on companies that are entering the realization or volume expansion phase, particularly those with overseas capabilities, such as Innovent Biologics, CanSino Biologics, and Eucure Biopharma [1] - The upcoming 2024 national medical insurance negotiations are anticipated to further impact the innovative drug field positively, creating opportunities for valuation reconstruction in the pharmaceutical sector [1]